FDA Approved: SENSIPAR — Supplemental Application (Amgen Inc)

View source ↗

Summary

FDA approves a supplemental NDA for SENSIPAR (cinacalcet hydrochloride) submitted by Amgen, resulting in updated labeling and potential new/expanded indications…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercalcemia Associated with Parathyroid Carcinoma
• Hyperparathyroidism

Drugs mentioned

• SENSIPAR (CINACALCET HYDROCHLORIDE)

Snippet

SUPPL AP for SENSIPAR (CINACALCET HYDROCHLORIDE)